Hungary
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.68 (0.63 - 0.74) | 2019 | Modelled | IHME |
0.69 (0.64 - 0.74) | 2018 | Modelled | IHME |
0.69 (0.64 - 0.75) | 2017 | Modelled | IHME |
0.69 (0.64 - 0.75) | 2016 | Modelled | IHME |
0.69 (0.64 - 0.75) | 2015 | Modelled | IHME |
0.69 (0.64 - 0.75) | 2014 | Modelled | IHME |
0.69 (0.64 - 0.75) | 2013 | Modelled | IHME |
0.7 (0.64 - 0.76) | 2012 | Modelled | IHME |
0.7 (0.64 - 0.76) | 2011 | Modelled | IHME |
0.7 (0.65 - 0.77) | 2010 | Modelled | IHME |
0.7 (0.65 - 0.77) | 2009 | Modelled | IHME |
0.7 (0.65 - 0.77) | 2008 | Modelled | IHME |
0.71 (0.65 - 0.77) | 2007 | Modelled | IHME |
0.71 (0.65 - 0.77) | 2006 | Modelled | IHME |
0.71 (0.65 - 0.77) | 2005 | Modelled | IHME |
0.71 (0.65 - 0.77) | 2004 | Modelled | IHME |
0.71 (0.65 - 0.78) | 2003 | Modelled | IHME |
0.72 (0.65 - 0.78) | 2002 | Modelled | IHME |
0.72 (0.65 - 0.79) | 2001 | Modelled | IHME |
0.72 (0.65 - 0.79) | 2000 | Modelled | IHME |
0.73 (0.65 - 0.79) | 1999 | Modelled | IHME |
0.73 (0.66 - 0.79) | 1998 | Modelled | IHME |
0.73 (0.67 - 0.79) | 1997 | Modelled | IHME |
0.74 (0.67 - 0.79) | 1996 | Modelled | IHME |
0.74 (0.67 - 0.80) | 1995 | Modelled | IHME |
0.74 (0.67 - 0.80) | 1994 | Modelled | IHME |
0.74 (0.68 - 0.80) | 1993 | Modelled | IHME |
0.74 (0.67 - 0.81) | 1992 | Modelled | IHME |
0.74 (0.67 - 0.81) | 1991 | Modelled | IHME |
0.74 (0.66 - 0.82) | 1990 | Modelled | IHME |
0.4 (0.10 - 1) | 2009 | Survey/reported | Treso B, 2012 |
0.45 (0.19 - 0.96) | 2015 | Modelled | WHO |
0.4 (0.40 - 0.50) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
0.4 (0.10 - 1) | 2009 | Survey/reported | ECDC |
Showing out of
Show more
Children under-5 years
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.22 (0.16 - 0.30) | 2019 | Modelled | IHME |
0.22 (0.17 - 0.29) | 2018 | Modelled | IHME |
0.22 (0.17 - 0.29) | 2017 | Modelled | IHME |
0.22 (0.16 - 0.29) | 2016 | Modelled | IHME |
0.22 (0.16 - 0.30) | 2015 | Modelled | IHME |
0.22 (0.16 - 0.30) | 2014 | Modelled | IHME |
0.22 (0.16 - 0.30) | 2013 | Modelled | IHME |
0.23 (0.16 - 0.30) | 2012 | Modelled | IHME |
0.23 (0.16 - 0.30) | 2011 | Modelled | IHME |
0.23 (0.17 - 0.31) | 2010 | Modelled | IHME |
0.23 (0.17 - 0.30) | 2009 | Modelled | IHME |
0.23 (0.17 - 0.30) | 2008 | Modelled | IHME |
0.23 (0.17 - 0.30) | 2007 | Modelled | IHME |
0.23 (0.17 - 0.31) | 2006 | Modelled | IHME |
0.23 (0.17 - 0.31) | 2005 | Modelled | IHME |
0.23 (0.17 - 0.31) | 2004 | Modelled | IHME |
0.24 (0.17 - 0.31) | 2003 | Modelled | IHME |
0.24 (0.18 - 0.31) | 2002 | Modelled | IHME |
0.24 (0.18 - 0.31) | 2001 | Modelled | IHME |
0.24 (0.18 - 0.32) | 2000 | Modelled | IHME |
0.25 (0.19 - 0.32) | 1999 | Modelled | IHME |
0.25 (0.19 - 0.33) | 1998 | Modelled | IHME |
0.26 (0.19 - 0.33) | 1997 | Modelled | IHME |
0.27 (0.20 - 0.34) | 1996 | Modelled | IHME |
0.27 (0.20 - 0.35) | 1995 | Modelled | IHME |
0.27 (0.20 - 0.35) | 1994 | Modelled | IHME |
0.27 (0.20 - 0.35) | 1993 | Modelled | IHME |
0.27 (0.20 - 0.35) | 1992 | Modelled | IHME |
0.27 (0.20 - 0.35) | 1991 | Modelled | IHME |
0.27 (0.19 - 0.35) | 1990 | Modelled | IHME |
0.44 (0.18 - 0.97) | 2015 | Modelled | WHO |
Showing out of
Show more
Prisoners
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.5 (1.20 - 1.80) | 2009 | Survey/reported | Treso B et al, 2012 |
1.5 | 2012 | Survey/reported | ECDC |
Showing out of
Show more
Number of people living with chronic HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
77,266 (68,566 - 85,062) | 1990 | Modelled | IHME |
77,093 (69,493 - 84,251) | 1991 | Modelled | IHME |
76,872 (69,773 - 83,757) | 1992 | Modelled | IHME |
76,599 (69,844 - 83,216) | 1993 | Modelled | IHME |
76,316 (69,664 - 82,604) | 1994 | Modelled | IHME |
76,027 (69,446 - 82,395) | 1995 | Modelled | IHME |
75,677 (69,235 - 81,705) | 1996 | Modelled | IHME |
75,235 (68,759 - 81,559) | 1997 | Modelled | IHME |
74,719 (67,924 - 81,096) | 1998 | Modelled | IHME |
74,178 (66,887 - 80,812) | 1999 | Modelled | IHME |
73,691 (66,147 - 80,914) | 2000 | Modelled | IHME |
73,231 (66,331 - 80,096) | 2001 | Modelled | IHME |
72,729 (66,141 - 79,541) | 2002 | Modelled | IHME |
72,213 (65,945 - 78,931) | 2003 | Modelled | IHME |
71,743 (65,842 - 78,263) | 2004 | Modelled | IHME |
71,370 (65,443 - 77,683) | 2005 | Modelled | IHME |
71,079 (65,457 - 77,360) | 2006 | Modelled | IHME |
70,811 (65,380 - 77,077) | 2007 | Modelled | IHME |
70,553 (65,131 - 76,736) | 2008 | Modelled | IHME |
70,276 (64,865 - 76,522) | 2009 | Modelled | IHME |
69,945 (64,505 - 76,339) | 2010 | Modelled | IHME |
69,518 (64,021 - 75,570) | 2011 | Modelled | IHME |
69,006 (63,683 - 74,807) | 2012 | Modelled | IHME |
68,492 (63,271 - 74,383) | 2013 | Modelled | IHME |
68,054 (62,743 - 74,214) | 2014 | Modelled | IHME |
67,748 (62,496 - 74,076) | 2015 | Modelled | IHME |
67,621 (62,772 - 73,285) | 2016 | Modelled | IHME |
67,473 (62,445 - 73,229) | 2017 | Modelled | IHME |
66,908 (62,040 - 72,223) | 2018 | Modelled | IHME |
65,954 (61,121 - 71,681) | 2019 | Modelled | IHME |
40,000 (36,000 - 44,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
Showing out of
Show more
HBV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
11.5 (8.58 - 15.30) | 2019 | Modelled | IHME |
11.6 (8.74 - 15) | 2018 | Modelled | IHME |
11.3 (8.68 - 14.30) | 2017 | Modelled | IHME |
11.3 (8.65 - 14.20) | 2016 | Modelled | IHME |
11.7 (8.96 - 14.70) | 2015 | Modelled | IHME |
11.7 (9 - 14.70) | 2014 | Modelled | IHME |
11.9 (9.21 - 15) | 2013 | Modelled | IHME |
12.9 (9.93 - 16.20) | 2012 | Modelled | IHME |
13.7 (10.60 - 17.10) | 2011 | Modelled | IHME |
14.7 (11.40 - 18.30) | 2010 | Modelled | IHME |
15.8 (12.20 - 19.50) | 2009 | Modelled | IHME |
16.3 (12.70 - 20.10) | 2008 | Modelled | IHME |
17.3 (13.50 - 21.30) | 2007 | Modelled | IHME |
17.5 (13.60 - 21.50) | 2006 | Modelled | IHME |
18 (14 - 22.20) | 2005 | Modelled | IHME |
18.2 (14.20 - 22.30) | 2004 | Modelled | IHME |
18.8 (14.60 - 23.10) | 2003 | Modelled | IHME |
18.9 (14.70 - 23.20) | 2002 | Modelled | IHME |
19.2 (15 - 23.70) | 2001 | Modelled | IHME |
20.3 (15.70 - 25) | 2000 | Modelled | IHME |
21.9 (17 - 27.10) | 1999 | Modelled | IHME |
22.3 (17.40 - 27.50) | 1998 | Modelled | IHME |
22.1 (17.30 - 27.30) | 1997 | Modelled | IHME |
22.8 (17.80 - 28) | 1996 | Modelled | IHME |
25 (19.50 - 30.80) | 1995 | Modelled | IHME |
25.4 (19.90 - 31.10) | 1994 | Modelled | IHME |
25 (19.60 - 30.50) | 1993 | Modelled | IHME |
23.3 (18.30 - 28.50) | 1992 | Modelled | IHME |
20.5 (16.20 - 25) | 1991 | Modelled | IHME |
19.3 (15.30 - 23.50) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
1,115 (830 - 1,477) | 2019 | Modelled | IHME |
1,129 (849 - 1,454) | 2018 | Modelled | IHME |
1,105 (846 - 1,393) | 2017 | Modelled | IHME |
1,105 (847 - 1,392) | 2016 | Modelled | IHME |
1,148 (880 - 1,444) | 2015 | Modelled | IHME |
1,155 (886 - 1,445) | 2014 | Modelled | IHME |
1,180 (909 - 1,485) | 2013 | Modelled | IHME |
1,277 (983 - 1,602) | 2012 | Modelled | IHME |
1,362 (1,054 - 1,697) | 2011 | Modelled | IHME |
1,465 (1,134 - 1,820) | 2010 | Modelled | IHME |
1,575 (1,223 - 1,947) | 2009 | Modelled | IHME |
1,630 (1,268 - 2,014) | 2008 | Modelled | IHME |
1,738 (1,353 - 2,143) | 2007 | Modelled | IHME |
1,757 (1,370 - 2,165) | 2006 | Modelled | IHME |
1,821 (1,415 - 2,241) | 2005 | Modelled | IHME |
1,837 (1,432 - 2,253) | 2004 | Modelled | IHME |
1,901 (1,482 - 2,341) | 2003 | Modelled | IHME |
1,921 (1,497 - 2,360) | 2002 | Modelled | IHME |
1,959 (1,525 - 2,408) | 2001 | Modelled | IHME |
2,070 (1,597 - 2,552) | 2000 | Modelled | IHME |
2,244 (1,743 - 2,768) | 1999 | Modelled | IHME |
2,289 (1,785 - 2,822) | 1998 | Modelled | IHME |
2,270 (1,775 - 2,804) | 1997 | Modelled | IHME |
2,342 (1,829 - 2,882) | 1996 | Modelled | IHME |
2,580 (2,014 - 3,177) | 1995 | Modelled | IHME |
2,620 (2,058 - 3,210) | 1994 | Modelled | IHME |
2,582 (2,028 - 3,153) | 1993 | Modelled | IHME |
2,410 (1,893 - 2,949) | 1992 | Modelled | IHME |
2,128 (1,679 - 2,596) | 1991 | Modelled | IHME |
2,006 (1,590 - 2,445) | 1990 | Modelled | IHME |
767 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
20 (14 - 28) | 2019 | Modelled | IHME |
20 (15 - 28) | 2018 | Modelled | IHME |
21 (15 - 29) | 2017 | Modelled | IHME |
21 (15 - 29) | 2016 | Modelled | IHME |
21 (15 - 29) | 2015 | Modelled | IHME |
21 (15 - 29) | 2014 | Modelled | IHME |
21 (15 - 29) | 2013 | Modelled | IHME |
21 (15 - 29) | 2012 | Modelled | IHME |
21 (15 - 29) | 2011 | Modelled | IHME |
22 (15 - 29) | 2010 | Modelled | IHME |
22 (16 - 29) | 2009 | Modelled | IHME |
22 (16 - 29) | 2008 | Modelled | IHME |
22 (16 - 30) | 2007 | Modelled | IHME |
22 (16 - 30) | 2006 | Modelled | IHME |
22 (16 - 30) | 2005 | Modelled | IHME |
22 (16 - 30) | 2004 | Modelled | IHME |
22 (16 - 30) | 2003 | Modelled | IHME |
22 (16 - 30) | 2002 | Modelled | IHME |
22 (16 - 29) | 2001 | Modelled | IHME |
22 (16 - 29) | 2000 | Modelled | IHME |
22 (16 - 29) | 1999 | Modelled | IHME |
22 (16 - 30) | 1998 | Modelled | IHME |
22 (16 - 30) | 1997 | Modelled | IHME |
22 (15 - 30) | 1996 | Modelled | IHME |
22 (15 - 30) | 1995 | Modelled | IHME |
22 (15 - 30) | 1994 | Modelled | IHME |
22 (15 - 30) | 1993 | Modelled | IHME |
21 (15 - 30) | 1992 | Modelled | IHME |
21 (15 - 29) | 1991 | Modelled | IHME |
21 (15 - 29) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
21 | 2017 | Survey/reported | EMCDDA, 2019 |
48 (32 - 91) | 2016 | Survey/reported | Hungary National Institute for Health Development, 2016 |
21 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.21 (0.98 - 1.49) | 2019 | Modelled | IHME |
1.2 (0.98 - 1.47) | 2018 | Modelled | IHME |
1.2 (0.97 - 1.47) | 2017 | Modelled | IHME |
1.21 (0.99 - 1.47) | 2016 | Modelled | IHME |
1.22 (1 - 1.49) | 2015 | Modelled | IHME |
1.23 (1.01 - 1.50) | 2014 | Modelled | IHME |
1.25 (1.03 - 1.52) | 2013 | Modelled | IHME |
1.27 (1.04 - 1.54) | 2012 | Modelled | IHME |
1.28 (1.05 - 1.56) | 2011 | Modelled | IHME |
1.3 (1.06 - 1.58) | 2010 | Modelled | IHME |
1.31 (1.07 - 1.61) | 2009 | Modelled | IHME |
1.33 (1.08 - 1.62) | 2008 | Modelled | IHME |
1.34 (1.09 - 1.64) | 2007 | Modelled | IHME |
1.36 (1.10 - 1.66) | 2006 | Modelled | IHME |
1.38 (1.11 - 1.68) | 2005 | Modelled | IHME |
1.4 (1.13 - 1.71) | 2004 | Modelled | IHME |
1.43 (1.16 - 1.74) | 2003 | Modelled | IHME |
1.46 (1.19 - 1.78) | 2002 | Modelled | IHME |
1.49 (1.22 - 1.82) | 2001 | Modelled | IHME |
1.52 (1.24 - 1.85) | 2000 | Modelled | IHME |
1.54 (1.26 - 1.88) | 1999 | Modelled | IHME |
1.55 (1.27 - 1.90) | 1998 | Modelled | IHME |
1.57 (1.29 - 1.92) | 1997 | Modelled | IHME |
1.59 (1.30 - 1.94) | 1996 | Modelled | IHME |
1.6 (1.31 - 1.96) | 1995 | Modelled | IHME |
1.61 (1.32 - 1.97) | 1994 | Modelled | IHME |
1.63 (1.34 - 1.98) | 1993 | Modelled | IHME |
1.64 (1.34 - 1.99) | 1992 | Modelled | IHME |
1.65 (1.35 - 1.99) | 1991 | Modelled | IHME |
1.66 (1.35 - 2.02) | 1990 | Modelled | IHME |
0.5 (0.30 - 0.60) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.51 (0.28 - 0.54) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.5 (0.20 - 1.10) | 2009 | Survey/reported | Treso B, 2012 |
0.8 (0.40 - 2.70) | 2014 | Survey/reported | Gower et al, 2014 |
0.8 (0.40 - 2.70) | 2014 | Survey/reported | Gower et al, 2014 |
0.5 (0.20 - 1.10) | 2009 | Survey/reported | ECDC |
Showing out of
Show more
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
46.6 (30.40 - 62.80) | 2015 | Modelled | Degenhardt L et al, 2017 |
24.1 (20.80 - 27.60) | 2011 | Survey/reported | EMCDDA |
49.7 | 2015 | Survey/reported | ECDC |
Showing out of
Show more
Prisoners
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
4.9 (4.30 - 5.60) | 2009 | Survey/reported | Treso B et al, 2012 |
4.9 | 2012 | Survey/reported | ECDC |
Showing out of
Show more
Number of people living with chronic HCV (RNA+/cAg)
National
DownloadValue | Year | Type | Source |
---|---|---|---|
172,599 (140,133 - 209,961) | 1990 | Modelled | IHME |
171,314 (139,758 - 206,785) | 1991 | Modelled | IHME |
169,895 (139,238 - 205,858) | 1992 | Modelled | IHME |
168,327 (138,344 - 205,012) | 1993 | Modelled | IHME |
166,702 (136,765 - 203,616) | 1994 | Modelled | IHME |
165,022 (135,001 - 202,063) | 1995 | Modelled | IHME |
163,273 (133,998 - 199,787) | 1996 | Modelled | IHME |
161,416 (132,219 - 197,245) | 1997 | Modelled | IHME |
159,373 (130,337 - 195,174) | 1998 | Modelled | IHME |
157,131 (128,560 - 191,927) | 1999 | Modelled | IHME |
154,742 (126,075 - 188,818) | 2000 | Modelled | IHME |
151,892 (123,906 - 185,532) | 2001 | Modelled | IHME |
148,468 (120,775 - 181,127) | 2002 | Modelled | IHME |
144,845 (117,617 - 176,771) | 2003 | Modelled | IHME |
141,458 (114,557 - 172,973) | 2004 | Modelled | IHME |
138,721 (112,143 - 169,552) | 2005 | Modelled | IHME |
136,615 (111,080 - 166,823) | 2006 | Modelled | IHME |
134,771 (109,958 - 164,669) | 2007 | Modelled | IHME |
133,077 (108,582 - 162,601) | 2008 | Modelled | IHME |
131,389 (106,880 - 160,528) | 2009 | Modelled | IHME |
129,557 (105,563 - 157,927) | 2010 | Modelled | IHME |
127,554 (104,088 - 154,873) | 2011 | Modelled | IHME |
125,477 (103,118 - 152,463) | 2012 | Modelled | IHME |
123,442 (101,600 - 150,327) | 2013 | Modelled | IHME |
121,548 (99,465 - 148,092) | 2014 | Modelled | IHME |
119,860 (97,939 - 146,537) | 2015 | Modelled | IHME |
118,158 (96,646 - 143,685) | 2016 | Modelled | IHME |
117,018 (94,985 - 143,291) | 2017 | Modelled | IHME |
116,715 (94,972 - 143,165) | 2018 | Modelled | IHME |
116,957 (94,966 - 143,818) | 2019 | Modelled | IHME |
52,000 (29,000 - 55,000) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue | Year | Type | Source |
---|---|---|---|
11,400 (6,300 - 12,100) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
6.65 (4.67 - 9.31) | 2019 | Modelled | IHME |
6.72 (4.89 - 9.28) | 2018 | Modelled | IHME |
6.56 (4.88 - 8.94) | 2017 | Modelled | IHME |
6.53 (4.87 - 8.88) | 2016 | Modelled | IHME |
6.76 (5.04 - 9.07) | 2015 | Modelled | IHME |
6.8 (5.06 - 9.16) | 2014 | Modelled | IHME |
6.96 (5.21 - 9.33) | 2013 | Modelled | IHME |
7.53 (5.65 - 10.10) | 2012 | Modelled | IHME |
8.08 (6.07 - 10.80) | 2011 | Modelled | IHME |
8.67 (6.54 - 11.60) | 2010 | Modelled | IHME |
9.27 (7 - 12.40) | 2009 | Modelled | IHME |
9.54 (7.25 - 12.80) | 2008 | Modelled | IHME |
10.1 (7.65 - 13.30) | 2007 | Modelled | IHME |
10.1 (7.61 - 13.30) | 2006 | Modelled | IHME |
10.3 (7.76 - 13.70) | 2005 | Modelled | IHME |
10.4 (7.80 - 13.70) | 2004 | Modelled | IHME |
10.7 (7.96 - 14.10) | 2003 | Modelled | IHME |
10.7 (7.96 - 14.10) | 2002 | Modelled | IHME |
10.8 (8.08 - 14.40) | 2001 | Modelled | IHME |
11.3 (8.39 - 15.10) | 2000 | Modelled | IHME |
12.2 (9.07 - 16.40) | 1999 | Modelled | IHME |
12.5 (9.31 - 16.70) | 1998 | Modelled | IHME |
12.5 (9.31 - 16.70) | 1997 | Modelled | IHME |
13 (9.70 - 17.30) | 1996 | Modelled | IHME |
14.5 (10.90 - 19.20) | 1995 | Modelled | IHME |
14.8 (11.20 - 19.60) | 1994 | Modelled | IHME |
14.6 (11.10 - 19.40) | 1993 | Modelled | IHME |
13.8 (10.50 - 18.10) | 1992 | Modelled | IHME |
12.3 (9.46 - 16.10) | 1991 | Modelled | IHME |
11.7 (9 - 15.20) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
644 (452 - 900) | 2019 | Modelled | IHME |
653 (475 - 902) | 2018 | Modelled | IHME |
640 (476 - 872) | 2017 | Modelled | IHME |
639 (477 - 869) | 2016 | Modelled | IHME |
664 (495 - 891) | 2015 | Modelled | IHME |
669 (499 - 903) | 2014 | Modelled | IHME |
687 (515 - 922) | 2013 | Modelled | IHME |
745 (560 - 1,000) | 2012 | Modelled | IHME |
803 (603 - 1,072) | 2011 | Modelled | IHME |
864 (651 - 1,158) | 2010 | Modelled | IHME |
926 (700 - 1,242) | 2009 | Modelled | IHME |
956 (727 - 1,285) | 2008 | Modelled | IHME |
1,010 (768 - 1,337) | 2007 | Modelled | IHME |
1,015 (766 - 1,341) | 2006 | Modelled | IHME |
1,043 (783 - 1,380) | 2005 | Modelled | IHME |
1,049 (789 - 1,383) | 2004 | Modelled | IHME |
1,080 (807 - 1,429) | 2003 | Modelled | IHME |
1,085 (809 - 1,437) | 2002 | Modelled | IHME |
1,101 (822 - 1,464) | 2001 | Modelled | IHME |
1,153 (856 - 1,538) | 2000 | Modelled | IHME |
1,247 (928 - 1,677) | 1999 | Modelled | IHME |
1,280 (954 - 1,717) | 1998 | Modelled | IHME |
1,283 (956 - 1,718) | 1997 | Modelled | IHME |
1,338 (998 - 1,783) | 1996 | Modelled | IHME |
1,491 (1,125 - 1,983) | 1995 | Modelled | IHME |
1,524 (1,155 - 2,025) | 1994 | Modelled | IHME |
1,515 (1,145 - 2,009) | 1993 | Modelled | IHME |
1,428 (1,092 - 1,877) | 1992 | Modelled | IHME |
1,280 (982 - 1,673) | 1991 | Modelled | IHME |
1,213 (935 - 1,577) | 1990 | Modelled | IHME |
965 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
26 (18 - 34) | 2019 | Modelled | IHME |
26 (18 - 34) | 2018 | Modelled | IHME |
26 (18 - 34) | 2017 | Modelled | IHME |
26 (18 - 34) | 2016 | Modelled | IHME |
26 (18 - 34) | 2015 | Modelled | IHME |
26 (18 - 34) | 2014 | Modelled | IHME |
26 (18 - 34) | 2013 | Modelled | IHME |
25 (18 - 33) | 2012 | Modelled | IHME |
25 (18 - 33) | 2011 | Modelled | IHME |
25 (18 - 33) | 2010 | Modelled | IHME |
25 (18 - 33) | 2009 | Modelled | IHME |
25 (18 - 32) | 2008 | Modelled | IHME |
25 (18 - 32) | 2007 | Modelled | IHME |
25 (18 - 32) | 2006 | Modelled | IHME |
25 (18 - 32) | 2005 | Modelled | IHME |
25 (17 - 32) | 2004 | Modelled | IHME |
24 (17 - 32) | 2003 | Modelled | IHME |
24 (17 - 32) | 2002 | Modelled | IHME |
25 (17 - 32) | 2001 | Modelled | IHME |
24 (17 - 32) | 2000 | Modelled | IHME |
24 (17 - 32) | 1999 | Modelled | IHME |
25 (17 - 32) | 1998 | Modelled | IHME |
25 (17 - 32) | 1997 | Modelled | IHME |
25 (17 - 33) | 1996 | Modelled | IHME |
25 (17 - 33) | 1995 | Modelled | IHME |
25 (17 - 32) | 1994 | Modelled | IHME |
24 (17 - 32) | 1993 | Modelled | IHME |
24 (17 - 32) | 1992 | Modelled | IHME |
24 (17 - 32) | 1991 | Modelled | IHME |
24 (17 - 32) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
21 | 2017 | Survey/reported | EMCDDA, 2019 |
48 (32 - 91) | 2016 | Survey/reported | Hungary National Institute for Health Development, 2016 |
21 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Number of persons treated for HCV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
838 | 2017 | Survey/reported | ECDC, 2019 |
838 | 2017 | Survey/reported | The European Centre for Disease Prevention and Control, 2019 |
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
Hepatitis related deaths (national)
Prevalence < 5
HBV
0.22
(%)
2019, latest modelled
(0.16 - 0.30(%))
IHME
Prevalence PWID
HCV
49.70
(%)
2015, survey/surveillance
ECDC
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines